Part 7: The era of reperfusion - Section 1: Acute coronary syndromes (acute myocardial infarction)

Resuscitation

Volumn 46, Issue 1-3, 2000, Pages 203-237

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; ANTIARRHYTHMIC AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DALTEPARIN; DIGITALIS; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; ENALAPRIL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; LIDOCAINE; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM; MORPHINE; NADROPARIN; NIFEDIPINE; NITROPRUSSIDE SODIUM; NORADRENALIN; RETEPLASE; STREPTOKINASE; TIROFIBAN; UNINDEXED DRUG; VERAPAMIL;

ACUTE HEART INFARCTION; ALGORITHM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; OXYGEN THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

EID: 0034705928     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9572(00)00281-1     Document Type: Note

References (282)

1. Chesebro J.H., Rauch U., Fuster V., Badimon J.J. Pathogenesis of thrombosis in coronary artery disease. Haemostasis. 27:((suppl 1)):1997;12-18.
2. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am J Cardiol. 76:1995;24C-33C.
3. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 326:1992;242-250.
4. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 326:1992;310-318.
5. Fuster V., Fallon J.T., Badimon J.J., Nemerson Y. The unstable atherosclerotic plaque: clinical significance and therapeutic intervention. Thromb Haemost. 78:1997;247-255.
6. Davies M.J. Anatomic features in victims of sudden coronary death: coronary artery pathology. Circulation. 85:((suppl I)):1992;. I-19-I-24.
7. Burke A.P., Farb A., Malcom G.T., Liang Y., Smialek J.E., Virmani R. Plaque rupture and sudden death related to exertion in men with coronary artery disease. JAMA. 281:1999;921-926.
8. Farb A., Tang A.L., Burke A.P., Sessums L., Liang Y., Virmani R. Sudden coronary death: frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation. 92:1995;1701-1709.
9. Virmani R., Burke A.P., Farb A. Plaque morphology in sudden coronary death. Cardiologia. 43:1998;267-271.
10. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 71:1985;699-708.
11. Gunnar R., Bourdillon P., Dixon D., Fuster V., Karp R., Kennedy J., et al. ACC/AHA Guidelines for the Early Management of Patients with Acute Myocardial Infarction. Circulation. 82:1990;664-707.
12. Ryan T.J., Anderson J.L., Antman E.M., Braniff B.A., Brooks N.H., Califf R.M., Hillis L.D., Hiratzka L.F., Rapaport E., Riegel B.J., Russell R.O., Smith E.E. III, Weaver W.D. ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 94:1996;2341-2345.
13. Ryan T. Update: guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol. 34:1999;890-911.
14. Braunwald E., Jones R.H., Mark D.B., Brown J., Brown L., Cheitlin M.D., Concannon C.A., Cowan M., Edwards C., Fuster V., et al. Diagnosing and managing unstable angina: Agency for Health Care Policy and Research. Circulation. 90:1994;613-622.
15. Acute myocardial infarction: pre-hospital and in-hospital management. Eur Heart J. 17:1996;43-63.
16. ACC/AHA guidelines for the management of unstable angina. Circulation. 2000;. In press.
17. The pre-hospital management of acute heart attacks: recommendations of a task force of the European Society of Cardiology and the European Resuscitation Council. Eur Heart J 1998;19:1140-1164.
18. Ridker P.M., Antman E.M. Pathogenesis and pathology of coronary heart disease syndromes. J Thromb Thrombolysis. 8:1999;167-189.
19. Davies M.J. The pathophysiology of acute coronary syndromes. Heart. 83:2000;361-366.
20. Ambrose J.A., Fuster V. Can we predict future acute coronary events in patients with stable coronary artery disease? [editorial; comment]. JAMA. 277:1997;343-344.
21. Ambrose J.A., Winters S.L., Arora R.R., Haft J.I., Goldstein J., Rentrop K.P., Gorlin R., Fuster V. Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol. 6:1985;1233-1238.
22. Azar R., Waters D. The inflammatory etiology of unstable angina. Am Heart J. 132:1996;1101-1106.
23. Anderson J.L., Carlquist J.F., Muhlestein J.B., Horne B.D., Elmer S.P. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol. 32:1998;35-41.
24. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group [published erratum appears in Lancet. 1994;343:742] [see comments]. Lancet. 343:1994;311-322.
25. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia [see comments]. Circulation. 89:1994;1545-1556.
26. Topol E.J. Inflammation and embolization in ischemic heart disease. Invasive Cardiol. 12:((suppl B)):2000;2B-7B. [MEDLINE record in process].
27. Erbel R., Heusch G. Coronary microembolization: its role in acute coronary syndromes and interventions. Herz. 24:1999;558-575.
28. Saber R.S., Edwards W.D., Bailey K.R., McGovern T.W., Schwartz R.S., Holmes D.R. Jr. Coronary embolization after balloon angioplasty or thrombolytic therapy: an autopsy study of 32 cases. J Am Coll Cardiol. 22:1993;1283-1288.
29. Topol E.J., Yadav J.S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 101:2000;570-580.
30. Ravkilde J., Nissen H., Mickley H., Andersen P.E., Thayssen P., Horder M. Cardiac troponin T and CK-MB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris. Am Heart J. 127:1994;13-20.
31. Maseri A., L'Abbate A., Baroldi G., Chierchia S., Marzilli M., Ballestra A.M., Severi S., Parodi O., Biagini A., Distante A., Pesola A. Coronary vasospasm as a possible cause of myocardial infarction: a conclusion derived from the study of 'preinfarction' angina. N Engl J Med. 299:1978;1271-1277.
32. Sinapius D. Relationship between coronary-artery thrombosis and myocardial infarction [in German]. Dtsch Med Wochenschr. 97:1972;443-448.
33. Pantridge J.F., Geddes J.S. A mobile intensive-care unit in the management of myocardial infarction. Lancet. 2:1967;271-273.
34. Cohen M.C., Rohtla K.M., Lavery C.E., Muller J.E.', Mittleman M.A. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death [published erratum appears in Am J Cardiol. 1998;81:260]. Am J Cardiol. 79:1997;1512-1516.
35. Colquhoun M.C., Julien D.G. Sudden death in the community: the arrhythmia causing cardiac arrest and results of immediate resuscitation. Resuscitation. 24:1992;177A.
36. Rose L.B. The Oregon Coronary Ambulance Project: an experiment. Heart Lung. 3:1974;753-755.
37. Campbell, R.W., Murray, A., Julian, D.G., Ventricular arrhythmias in first 12 hours of acute myocardial infarction: natural history study. Br Heart J 1981;46:351-357. [37a] O'Doherty M, Taylor DI, Quinn E, Vincent R, Chamberlain DA. Five hundred patients with myocardial infarction monitored within one hour of symptoms. Br Med J 286 1983 1405-1408.
38. Campbell, R.W., Murray, A., Julian, D.G., Ventricular arrhythmias in first 12 hours of acute myocardial infarction: natural history study. Br Heart J 1981;46:351-357. [37a] O'Doherty M, Taylor DI, Quinn E, Vincent R, Chamberlain DA. Five hundred patients with myocardial infarction monitored within one hour of symptoms. Br Med J 286 1983 1405-1408.
39. Lie K.I., Wellens H.J., Downar E., Durrer D. Observations on patients with primary ventricular fibrillation complicating acute myocardial infarction. Circulation. 52:1975;755-759.
40. El-Sherif N., Myerburg R.J., Scherlag B.J., Befeler B., Aranda J.M., Castellanos A., Lazzara R. Electrocardiographic antecedents of primary ventricular fibrillation: value of the R-on-T phenomenon in myocardial infarction. Br Heart J. 38:1976;415-422.
41. Chiriboga D., Yarzebski J., Goldberg R.J., Gore J.M., Alpert J.S. Temporal trends (1975 through 1990) in the incidence and case-fatality rates of primary ventricular fibrillation complicating acute myocardial infarction: a communitywide perspective [see comments]. Circulation. 89:1994;998-1003.
42. Volpi A., Cavalli A., Franzosi M.G., Maggioni A., Mauri F., Santoro E., Tognoni G. One-year prognosis of primary ventricular fibrillation complicating acute myocardial infarction. Am J Cardiol. 63:1989;1174-1178.
43. Volpi A., De Vita C., Franzosi M.G., Geraci E., Maggioni A.P., Mauri F., Negri E., Santoro E., Tavazzi L., Tognoni G. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis: results of the GISSI-2 data base. Circulation. 88:1993;416-429.
44. Nicod P., Gilpin E., Dittrich H., Wright M., Engler R., Rittlemeyer J., Henning H., Ross J. Jr. Late clinical outcome in patients with early ventricular fibrillation after myocardial infarction. J Am Coll Cardiol. 11:1988;464-470.
45. Behar S., Goldbourt U., Reicher-Reiss H., Kaplinsky E. principal investigators of the SPRINT study. Prognosis of acute myocardial infarction complicated by primary ventricular fibrillation. Am J Cardiol. 66:1990;1208-1211.
46. Kerber R. Statement on early defibrillation from the American Heart Association. Circulation. 83:1991;2233.
47. Kloeck W., Cummins R.O., Chamberlain D., Bossaert L., Callanan V., Carli P., Christenson J., Connolly B., Ornato J.P., Sanders A., Steen P. Early defibrillation: an advisory statement from the Advanced Life Support Working Group of the International Liaison Committee on Resuscitation. Circulation. 95:1997;2183-2184.
48. Stults K., Brown D., Kerber R. Efficacy of an automated external defibrillator in the management of out-of-hospital cardiac arrest: validations of the diagnostic algorithm and initial experience in a rural environment. Circulation. 73:1986;701-709.
49. Eisenberg M.S., Cummins R.O. Defibrillation performed by the emergency medical technician. Circulation. 74:((suppl IV)):1986;. IV-9-IV-12.
50. Olson D., LaRochelle J., Fark D., Aprahamian C., Aufderheide T., Mateer J., Hartgarten K., Stueven H. EMT-defibrillation: the Wisconsin experience. Ann Emerg Med. 19:1990;613-614.
51. Cummins R.O., Eisenberg M.S., Litwin P.E., Graves J.R., Hearne T.R., Hallstrom A.P. Automatic external defibrillators used by emergency medical technicians: a controlled clinical trial. JAMA. 257:1987;1605-1610.
52. Mols P., Beaucarne E., Bruyninx J., Labruyere J.P., De Myttenaere L., Naeije N., Watteeuw G., Verset D., Flamand J.P. Early defibrillation by EMTs: the Brussels experience. Resuscitation. 27:1994;129-136.
53. Weisfeldt M.L., Kerber R.E., McGoldrick R.P., Moss A.J., Nichol G., Ornato J.P., Palmer D.G., Riegel B., Smith S.C. Jr. Public access defibrillation: a statement for healthcare professionals from the American Heart Association Task Force on Automatic External Defibrillation. Circulation. 92:1995;2763.
54. Weisfeldt M.L., Kerber R.E., McGoldrick R.P., Moss A.J., Nichol G., Ornato J.P., Palmer D.G., Riegel B., Smith S.C. Jr. Automatic External Defibrillation Task Force. American Heart Association report on the Public Access Defibrillation Conference December 8-10, 1994 [see comments]. Circulation. 92:1995;2740-2747.
55. Kern K.B. Public access defibrillation: a review. Heart. 80:1998;402-404.
56. Hjalmarson A., Herlitz J., Holmberg S., Ryden L., Swedberg K., Vedin A., Waagstein F., Waldenstrom A., Waldenstrom J., Wedel H., Wilhelmsen L., Wilhelmsson C. The Goteborg metoprolol trial: effects on mortality and morbidity in acute myocardial infarction. Circulation. 67:((suppl I)):1983;. I-26-I-32.
57. Risenfors M., Herlitz J., Berg C.H., Dellborg M., Gustavsson G., Gottfridsson C., Lomsky M., Swedberg K., Hjalmarsson A. Early treatment with thrombolysis and beta-blockade in suspected acute myocardial infarction: results from the TEAHAT Study. J Intern Med Suppl. 734:1991;35-42.
58. Lambrew C.T., Bowlby L.J., Rogers W.J., Chandra N.C., Weaver W.D. Factors influencing the time to thrombolysis in acute myocardial infarction: Time to Thrombolysis Substudy of the National Registry of Myocardial Infarction-1. Arch Intern Med. 157:1997;2577-2582.
59. Kereiakes D.J., Weaver W.D., Anderson J.L., Feldman T., Gibler B., Aufderheide T., Williams D.O., Martin L.H., Anderson L.C., Martin J.S., et al. Time delays in the diagnosis and treatment of acute myocardial infarction: a tale of eight cities: report from the Pre-hospital Study Group and the Cincinnati Heart Project. Am Heart J. 120:1990;773-780.
60. Weaver W.D. Time to thrombolytic treatment: factors affecting delay and their influence on outcome. J Am Coll Cardiol. 25:1995;3S-9S.
61. Hofgren C., Karlson B.W., Herlitz J. Prodromal symptoms in subsets of patients hospitalized for suspected acute myocardial infarction. Heart Lung. 24:1995;3-10.
62. Dempsey S.J., Dracup K., Moser D.K. Women's decision to seek care for symptoms of acute myocardial infarction. Heart Lung. 24:1995;444-456.
63. Solomon C.G., Lee T.H., Cook E.F., Weisberg M.C., Brand D.A., Rouan G.W., Goldman L. Comparison of clinical presentation of acute myocardial infarction in patients older than 65 years of age to younger patients: the Multicenter Chest Pain Study experience. Am J Cardiol. 63:1989;772-776.
64. Peberdy M., Ornato J. Coronary artery disease in women. Heart Dis Stroke. 1:1992;315-319.
65. Douglas P.S., Ginsburg G.S. The evaluation of chest pain in women. N Engl J Med. 334:1996;1311-1315.
66. Goff D.C. Jr, Feldman H.A., McGovern P.G., Goldberg R.J., Simons-Morton D.G., Cornell C.E./, Osganian S.K., Cooper L.S., Hedges J.R. Rapid Early Action for Coronary Treatment (REACT) Study Group. Prehospital delay in patients hospitalized with heart attack symptoms in the United States: the REACT trial [see comments]. Am Heart J. 138:1999;1046-1057.
67. Berglin Blohm M, Hartford M, Karlsson T, Herlitz J. Factors associated with pre-hospital and in-hospital delay time in acute myocardial infarction: a 6-year experience. J Intern Med 1998;243:243-250. [66a] Brown AL, Mann NC, Daya M, Goldberg R, Meischke H, Taylor J, Smith K, Osganian S, Cooper L. Demographic, belief, and situational factors influencing the decision to utilize emergency medical services among chest pain patients. Circulation 2000;102:173-178.
68. Berglin Blohm M, Hartford M, Karlsson T, Herlitz J. Factors associated with pre-hospital and in-hospital delay time in acute myocardial infarction: a 6-year experience. J Intern Med 1998;243:243-250. [66a] Brown AL, Mann NC, Daya M, Goldberg R, Meischke H, Taylor J, Smith K, Osganian S, Cooper L. Demographic, belief, and situational factors influencing the decision to utilize emergency medical services among chest pain patients. Circulation 2000;102:173-178.
69. Bleeker J.K., Simoons M.L., Erdman R.A., Leenders C.M., Kruyssen H.A., Lamers L.M., van der Does E. Patient and doctor delay in acute myocardial infarction: a study in Rotterdam, The Netherlands. Br J Gen Pract. 45:1995;181-184.
70. Goldberg R.J., McGovern P.G., Guggina T., Savageau J., Rosamond W.D., Luepker R.V. Prehospital delay in patients with acute coronary heart disease: concordance between patient interviews and medical records. Am Heart J. 135:1998;293-299.
71. Blohm M., Herlitz J., Schroder U., Hartford M., Karlson B.W., Risenfors M., Larsson E., Luepker R., Wennerblom B., Holmberg S. Reaction to a media campaign focusing on delay in acute myocardial infarction. Heart Lung. 20:1991;661-666.
72. Dracup K., Alonzo A.A., Atkins J.M., Bennett N.M., Braslow A., Clark L.T., Eisenberg M., Ferdinand K.C., Frye R., Green L., Hill M.N., Kennedy J.W., Kline-Rogers E., Moser D.K., Ornato J.P., Pitt B., Scott J.D., Selker H.P., Silva S.J., Thies W., Weaver W.D., Wenger N.K., White S.K. The physician's role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program. Ann Intern Med. 126:1997;645-651.
73. Weaver W.D., Cerqueira M., Hallstrom A.P., Litwin P.E., Martin J.S., Kudenchuk P.J., Eisenberg M. Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial [see comments]. JAMA. 270:1993;1211-1216.
74. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction [see comments]. N Engl J Med. 329:1993;383-389.
75. Schofer J., Buttner J., Geng G., Gutschmidt K., Herden H.N., Mathey D.G., Moecke H.P., Polster P., Raftopoulo A., Sheehan F.H., et al. Prehospital thrombolysis in acute myocardial infarction. Am J Cardiol. 66:1990;1429-1433.
76. Gibler W.B., Kereiakes D.J., Dean E.N., Martin L., Anderson L., Abbottsmith C.W., Blanton J., Blanton D., Morris J.A. Jr, Gibler C.D., et al. Prehospital diagnosis and treatment of acute myocardial infarction: a north-south perspective: the Cincinnati Heart Project and the Nashville Prehospital TPA Trial. Am Heart J. 121:1991;1-11.
77. Linderer T., Schroder R., Arntz R., Heineking M.L., Wunderlich W., Kohl K., Forycki F., Henzgen R., Wagner J. Prehospital thrombolysis: beneficial effects of very early treatment on infarct size and left ventricular function. J Am Coll Cardiol. 22:1993;1304-1310.
78. Rozenman Y., Gotsman M., Weiss T., Lotan C., Mosseri M., Sapoznikov D., Welber S., Nassar H., Hasin Y., Gilon D. Very early thrombolysis in acute myocardial infarction: a light at the end of the tunnel. Isr J Med Sci. 30:1994;99-107.
79. Rawles J. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol. 23:1994;1-5.
80. Rawles J.M. Myocardial salvage with early anistreplase treatment. Clin Cardiol. 20:1997;. III-6-III-10.
81. Rawles J.M. Quantification of the benefit of earlier thrombolytic therapy: five-year results of the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol. 30:1997;1181-1186.
82. Brouwer M.A., Martin J.S., Maynard C., Wirkus M., Litwin P.E., Verheugt F.W., Weaver W.D. Influence of early prehospital thrombolysis on mortality and event-free survival (the Myocardial Infarction Triage and Intervention [MITI] Randomized Trial). Am J Cardiol. 78:1996;497-502.
83. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction [see comments]. N Engl J Med. 329:1993;383-389.
84. Morrison L.J., Verbeek P.R., McDonald A.C., Sawadsky B.V., Cook D.J. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA. 283:2000;2686-2692.
85. Access to timely and optimal care of patients with acute coronary syndromes-community planning considerations: a report by the National Heart Attack Alert Program. J Thromb Thrombolysis. 6:1998;19-47.
86. Staffing and equipping emergency medical services system: rapid identification and treatment of acute myocardial infarction. Am J Emerg Med. 13:1995;58-66.
87. Kereiakes D.J., Gibler W.B., Martin L.H., Pieper K.S., Anderson L.C. Relative importance of emergency medical system transport and the prehospital electrocardiogram on reducing hospital time delay to therapy for acute myocardial infarction: a preliminary report from the Cincinnati Heart Project. Am Heart J. 123:1992;835-840.
88. Karagounis L., Ipsen S.K., Jessop M.R., Gilmore K.M., Valenti D.A., Clawson J.J., Teichman S., Anderson J.L. Impact of field-transmitted electrocardiography on time to in-hospital thrombolytic therapy in acute myocardial infarction. Am J Cardiol. 66:1990;786-791.
89. Foster D.B., Dufendach J.H., Barkdoll C.M., Mitchell B.K. Prehospital recognition of AMI using independent nurse/paramedic 12-lead ECG evaluation: impact on in-hospital times to thrombolysis in a rural community hospital. Am J Emerg Med. 12:1994;25-31.
90. Aufderheide T.P., Kereiakes D.J., Weaver W.D., Gibler W.B., Simoons M.L. Planning, implementation, and process monitoring for prehospital 12-lead ECG diagnostic programs. Prehospital Disaster Med. 11:1996;162-171.
91. Aufderheide T.P., Hendley G.E., Woo J., Lawrence S., Valley V., Teichman S.L. A prospective evaluation of prehospital 12-lead ECG application in chest pain patients. J Electrocardiol. 24:1992;8-13.
92. Aufderheide T.P., Haselow W.C., Hendley G.E., Robinson N.A., Armaganian L., Hargarten K.M., Olson D.W., Valley V.T., Stueven H.A. Feasibility of prehospital r-TPA therapy in chest pain patients. Ann Emerg Med. 21:1992;379-383.
93. Aufderheide T.P., Keelan M.H., Hendley G.E., Robinson N.A., Hastings T.E., Lewin R.F., Hewes H.F., Daniel A., Engle D., Gimbel B.K., et al. Milwaukee Prehospital Chest Pain Project: phase I: feasibility and accuracy of prehospital thrombolytic candidate selection. Am J Cardiol. 69:1992;991-996.
94. Pantridge J.F., Adgey A.A., Webb S.W. The first hour after the onset of acute myocardial infarction. Yu P.N., Goodwin J.F. Progress in Cardiology. 1975;173-178 Lea & Febiger, Philadelphia, Pa.
95. Grim P., Feldman T., Martin M., Donovan R., Nevins V., Childers R.W. Cellular telephone transmission of 12-lead electrocardiograms from ambulance to hospital. Am J Cardiol. 60:1987;715-720.
96. Kudenchuck P.J., Ho M.T., Litwin P., Martin J.S., Weaver W.D. Accuracy of cardiologist vs computerized ECG analysis in selecting patients for out-of-hospital thrombolytic therapy. Circulation. 80:((suppl II)):1989;II354.
97. Prehospital thrombolysis in acute myocardial infarction. Eur Heart J. 12:1991;965-967.
98. Weaver W., Cerqueira M., Hallstrom A., Litwin P., Martin J., Kudenchuk P., Eisenberg M. Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial (MITI). JAMA. 270:1993;1203-1210.
99. Staffing and equipping emergency medical services systems: rapid identification and treatment of acute myocardial infarction. Am J Emerg Med. 13:1995;58-66.
100. Canto J.G., Rogers W.J., Bowlby L.J., French W.J., Pearce D.J., Weaver W.D. The prehospital electrocardiogram in acute myocardial infarction: is its full potential being realized? J Am Coll Cardiol. 29:1997;498-505.
101. Bengtson J.R., Kaplan A.J., Pieper K.S., Wildermann N.M., Mark D.B., Pryor D.B., Phillips H.R. III, Califf R.M. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol. 20:1992;1482-1489.
102. Goldberg R.J., Gore J.M., Alpert J.S., Osganian V., de Groot J., Bade J., Chen Z., Frid D., Dalen J.E. Cardiogenic shock after acute myocardial infarction: incidence and mortality from a community-wide perspective, 1975 to 1988 [see comments]. N Engl J Med. 325:1991;1117-1122.
103. Hasdai D., Holmes D.R. Jr, Topol E.J., Berger P.B., Criger D.A., Hochman J.S., Bates E.R., Vahanian A., Armstrong P.W., Wilcox R., Ohman E.M., Califf R.M. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase: results from GUSTO-III: Global Use of Strategies to Open Occluded Coronary Arteries [see comments]. Eur Heart J. 20:1999;128-135.
104. Itoh T., Fukami K., Oriso S., Umemura J., Nakajima J., Obonai H., Hiramori K. Survival following cardiogenic shock caused by acute left main coronary artery total occlusion: a case report and review of the literature. Angiology. 48:1997;163-171.
105. Berger P.B., Holmes D.R. Jr, Stebbins A.L., Bates E.R., Califf R.M., Topol E.J. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial: an observational study. Circulation. 96:1997;122-127.
106. Holmes D.R. Jr, Califf R.M., Van de Werf F., Berger P.B., Bates E.R., Simoons M.L., White H.D., Thompson T.D., Topol E.J. Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial [see comments]. Lancet. 349:1997;75-78.
107. Tiefenbrunn A.J., Chandra N.C., French W.J., Gore J.M., Rogers W.J. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol. 31:1998;1240-1245.
108. Lee, L., Erbel, R., Brown, T.M., Laufer, N., Meyer, J., O'Neill, W.W., Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival. J Am Coll Cardiol. 1991;17:599-603. [106a] Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Early revascularization in acute myocardial infarction complicated by cardiogenic stock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 341 1999 625-634.
109. Lee, L., Erbel, R., Brown, T.M., Laufer, N., Meyer, J., O'Neill, W.W., Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival. J Am Coll Cardiol. 1991;17:599-603. [106a] Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Early revascularization in acute myocardial infarction complicated by cardiogenic stock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 341 1999 625-634.
110. Hochman J.S., Boland J., Sleeper L.A., Porway M., Brinker J., Col J., Jacobs A., Slater J., Miller D., Wasserman H., et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an International Registry [see comments]. Circulation. 91:1995;873-881.
111. Grines C.L. Aggressive intervention for myocardial infarction: angioplasty, stents, and intra-aortic balloon pumping. Am J Cardiol. 78:1996;29-34.
112. Ishihara M., Sato H., Tateishi H., Kawagoe T., Shimatani Y., Kurisu S., Sakai K. Intraaortic balloon pumping as adjunctive therapy to rescue coronary angioplasty after failed thrombolysis in anterior wall acute myocardial infarction. Am J Cardiol. 76:1995;73-75.
113. Nanas J.N., Nanas S.N., Kontoyannis D.A., Moussoutzani K.S., Hatzigeorgiou J.P., Heras P.B., Makaritsis K.P., Agapitos E.B., Moulopoulos S.D. Myocardial salvage by the use of reperfusion and intraaortic balloon pump: experimental study. Ann Thorac Surg. 61:1996;629-634.
114. Ohman E.M., Califf R.M., George B.S., Quigley P.J., Kereiakes D.J., Harrelson-Woodlief L., Candela R.J., Flanagan C., Stack R.S., Topol E.J. The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction [see comments]. Am Heart J. 121:1991;895-901.
115. Talley J.D., Ohman E.M., Mark D.B., George B.S., Leimberger J.D., Berdan L.G., Davidson-Ray L., Rawert M., Lam L.C., Phillips H.R., Califf R.M. Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction: intraaortic balloon pump. Am J Cardiol. 79:1997;590-594.
116. Madias J.E., Madias N.E., Hood W.B. Jr. Precordial ST-segment mapping, II: effects of oxygen inhalation on ischemic injury in patients with acute myocardial infarction. Circulation. 53:1976;411-417.
117. Maroko P.R., Radvany P., Braunwald E., Hale S.L. Reduction of infarct size by oxygen inhalation following acute coronary occlusion. Circulation. 52:1975;360-368.
118. Jugdutt B.I., Warnica J.W. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: effect of timing, dosage, and infarct location [published erratum appears in Circulation. 1989;79:1151]. Circulation. 78:1988;906-919.
119. Yusuf S., MacMahon S., Collins R., Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet. 1:1988;1088-1092.
120. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction [see comments]. Lancet. 345:1995;669-685.
121. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 2:1988;349-360.
122. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients [see comments] [published erratum appears in BMJ. 1994;308:1540]. BMJ. 308:1994;81-106.
123. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med. 23:1994;311-329.
124. Al-Mubarak N., Rogers W.J., Lambrew C.T., Bowlby L.J., French W.J. Consultation before thrombolytic therapy in acute myocardial infarction. Am J Cardiol. 83:(89-93):1999;A8.
125. Cannon C.P., McCabe C.H., Stone P.H., Rogers W.J., Schactman M., Thompson B.W., Pearce D.J., Diver D.J., Kells C., Feldman T., Williams M., Gibson R.S., Kronenberg M.W., Ganz L.I., Anderson H.V., Braunwald E. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study: Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol. 30:1997;133-140.
126. Merz C.N., Kelsey S.F., Pepine C.J., Reichek N., Reis S.E., Rogers W.J., Sharaf B.L., Sopko G. The Women's Ischemia Syndrome Evaluation (WISE) study: protocol design, methodology and feasibility report. J Am Coll Cardiol. 33:1999;1453-1461.
127. Lee T.H., Cook E.F., Weisberg M.C., Rouan G.W., Brand D.A., Goldman L. Impact of the availability of a prior electrocardiogram on the triage of the patient with acute chest pain [see comments]. J Gen Intern Med. 5:1990;381-388.
128. Bar F.W., Vermeer F., de Zwaan C., Ramentol M., Braat S., Simoons M.L., Hermens W.T., van der Laarse A., Verheugt F.W., Krauss X.H., et al. Value of admission electrocardiogram in predicting outcome of thrombolytic therapy in acute myocardial infarction: a randomized trial conducted by The Netherlands Interuniversity Cardiology Institute. Am J Cardiol. 59:1987;6-13.
129. Bar F.W., Volders P.G., Hoppener P., Vermeer F., Meyer J., Wellens H.J. Development of ST-segment elevation and Q- and R-wave changes in acute myocardial infarction and the influence of thrombolytic therapy. Am J Cardiol. 77:1996;337-343.
130. Califf R.M., O'Neil W., Stack R.S., Aronson L., Mark D.B., Mantell S., George B.S., Candela R.J., Kereiakes D.J., Abbottsmith C., et al. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Intern Med. 108:1988;658-662.
131. Krucoff M.W., Croll M.A., Pope J.E., Granger C.B., O'Connor C.M., Sigmon K.N., Wagner B.L., Ryan J.A., Lee K.L., Kereiakes D.J., et al. Continuous 12-lead ST-segment recovery analysis in the TAMI 7 study: performance of a noninvasive method for real-time detection of failed myocardial reperfusion. Circulation. 88:1993;437-446.
132. Krucoff M.W., Croll M.A., Pope J.E., Pieper K.S., Kanani P.M., Granger C.B., Veldkamp R.F., Wagner B.L., Sawchak S.T., Califf R.M. Continuously updated 12-lead ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographic observations. Am J Cardiol. 71:1993;145-151.
133. de Lemos J.A., Antman E.M., Gibson C.M., McCabe C.H., Giugliano R.P., Murphy S.A., Coulter S.A., Anderson K., Scherer J., Frey M.J., Van Der Wieken R., Van De Werf F., Braunwald E. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observations from the TIMI 14 trial. Circulation. 101:2000;239-243.
134. Shah A., Wagner G.S., Granger C.B., O'Connor C.M., Green C.L., Trollinger K.M., Califf R.M., Krucoff M.W. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis: reexamining the 'gold standard' for myocardial reperfusion assessment. J Am Coll Cardiol. 35:2000;666-672.
135. Schroder R., Zeymer U., Wegscheider K., Neuhaus K.L. Comparison of the predictive value of ST segment elevation resolution at 90 and 180 min after start of streptokinase in acute myocardial infarction: a substudy of the hirudin for improvement of thrombolysis (HIT)-4 study. Eur Heart J. 20:1999;1563-1571.
136. Boersma E., Pieper K.S., Steyerberg E.W., Wilcox R.G., Chang W.C., Lee K.L., Akkerhuis K.M., Harrington R.A., Deckers J.W., Armstrong P.W., Lincoff A.M., Califf R.M., Topol E.J., Simoons M.L. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation. 101:2000;2557-2567.
137. Antman E.M., Tanasijevic M.J., Thompson B., Schactman M., McCabe C.H., Cannon C.P., Fischer G.A., Fung A.Y., Thompson C., Wybenga D., Braunwald C.H. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes [see comments]. N Engl J Med. 335:1996;1342-1349.
138. Tanasijevic M.J., Cannon C.P., Antman E.M. The role of cardiac troponin-I (cTnI) in risk stratification of patients with unstable coronary artery disease. Clin Cardiol. 22:1999;13-16.
139. Heeschen C., Hamm C.W., Goldmann B., Deu A., Langenbrink L., White H.D. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 354:1999;1757-1762.
140. Lindahl B., Venge P., Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol. 29:1997;43-48.
141. Hamm C.W., Heeschen C., Goldmann B., Vahanian A., Adgey J., Miguel C.M., Rutsch W., Berger J., Kootstra J., Simoons M.L. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med. 340:1999;1623-1629.
142. Morrow D.A., Rifai N., Antman E.M., Weiner D.L., McCabe C.H., Cannon C.P., Braunwald E. C-reactive protein is a potent predictor of mortality
143. Rebuzzi A.G., Quaranta G., Liuzzo G., Caligiuri G., Lanza G.A., Gallimore J.R., Grillo R.L., Cianflone D., Biasucci L.M., Maseri A. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol. 82:1998;715-719.
144. Deleted in proof.
145. A comparison of reteplase with alteplase for acute myocardial infarction [see comments]. N Engl J Med. 337:1997;1118-1123.
146. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial [see comments]. Lancet. 354:1999;716-722.
147. Franzosi M.G., Santoro E., De Vita C., Geraci E., Lotto A., Maggioni A.P., Mauri F., Rovelli F., Santoro L., Tavazzi L., Tognoni G. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study [see comments]. Circulation. 98:1998;2659-2665.
148. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1:1986;397-402.
149. Deleted in proof.
150. Brodie B.R., Stuckey T.D., Kissling G., Hansen C.J., Weintraub R.A., Kelly T.A. Importance of infarct-related artery patency for recovery of left ventricular function and late survival after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 28:1996;319-325.
151. Puma J.A., Sketch M.H. Jr, Thompson T.D., Simes R.J., Morris D.C., White H.D., Topol E.J., Califf R.M. Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. Am J Cardiol. 83:1999;482-487.
152. Claeys M.J., Bosmans J., Veenstra L., Jorens P., De Raedt H., Vrints C.J. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: importance of microvascular reperfusion injury on clinical outcome. Circulation. 99:1999;1972-1977.
153. Gibson C.M., Murphy S.A., Rizzo M.J., Ryan K.A., Marble S.J., McCabe C.H., Cannon C.P., Van de Werf F., Braunwald E. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation. 99:1999;1945-1950.
154. Reimer K.A., Lowe J.E., Rasmussen M.M., Jennings R.B. The wavefront phenomenon of ischemic cell death, I: myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 56:1977;786-794.
155. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction [see comments]. Lancet. 342:1993;767-772.
156. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction [see comments]. Lancet 1993;342:759-766.
157. Simes R.J., Topol E.J., Holmes D.R. Jr, White H.D., Rutsch W.R., Vahanian A., Simoons M.L., Morris D., Betriu A., Califf R.M., et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion [see comments]. Circulation. 91:1995;1923-1928.
158. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction [see comments] [published erratum appears in N Engl J Med. 1994;330:516]. N Engl J Med. 329:1993;1615-1622.
159. Lamas G.A., Flaker G.C., Mitchell G., Smith S.C. Jr, Gersh B.J., Wun C.C., Moye L., Rouleau J.L., Rutherford J.D., Pfeffer M.A., et al. Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation. 92:1995;1101-1109.
160. Kim C.B., Braunwald E. Potential benefits of late reperfusion of infarcted myocardium: the open artery hypothesis. Circulation. 88:1993;2426-2436.
161. Hillis L.D., Forman S., Braunwald E. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 16:1990;313-315.
162. Simoons M.L., Maggioni A.P., Knatterud G., Leimberger J.D., de Jaegere P., van Domburg R., Boersma E., Franzosi M.G., Califf R., Schroder R., et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet. 342:1993;1523-1528.
163. Mauri F., Gasparini M., Barbonaglia L., Santoro E., Grazia Franzosi M., Tognoni G., Rovelli F. Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial). Am J Cardiol. 63:1989;1291-1295.
164. Mahaffey K.W., Granger C.B., Sloan M.A., Thompson T.D., Gore J.M., Weaver W.D., White H.D., Simoons M.L., Barbash G.I., Topol E.J., Califf R.M. Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. Circulation. 97:1998;757-764.
165. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries [see comments]. Circulation. 1995;92:2811-2818. [162a] White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD, Kleiman NS, Aylward PE, Gore JM, Vahanian A, Lee KL, Ross AM, Topol EJ. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial. Circulation. 1996;94:1826-1833.
166. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries [see comments]. Circulation. 1995;92:2811-2818. [162a] White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD, Kleiman NS, Aylward PE, Gore JM, Vahanian A, Lee KL, Ross AM, Topol EJ. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial. Circulation. 1996;94:1826-1833.
167. Maggioni A.P., Franzosi M.G., Santoro E., White H., Van de Werf F., Tognoni G. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment [see comments]. N Engl J Med. 327:1992;1-6.
168. Thiemann D.R., Coresh J., Schulman S.P., Gerstenblith G., Oetgen W.J., Powe N.R. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation. 101:2000;2239-2246.
169. Boersma E., Maas A.C., Deckers J.W., Simoons M.L. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 348:1996;771-775.
170. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction [see comments]. N Engl J Med. 329:1993;673-682.
171. Collins R., Peto R., Parish S., Sleight P. ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials [letter]. Am J Cardiol. 71:1993;1127-1130.
172. Aylward P.E., Wilcox R.G., Horgan J.H., White H.D., Granger C.B., Califf R.M., Topol E.J. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction: a randomized trial. Ann Intern Med. 125:1996;891-900.
173. Hollander J.E., Burstein J.L., Hoffman R.S., Shih R.D., Wilson L.D. Cocaine-associated myocardial infarction: clinical safety of thrombolytic therapy. Chest. 107:1995;1237-1241.
174. Anderson H.V., Cannon C.P., Stone P.H., Williams D.O., McCabe C.H., Knatterud G.L., Thompson B., Willerson J.T., Braunwald E. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial: a randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. 26:1995;1643-1650.
175. Langer A., Goodman S.G., Topol E.J., Charlesworth A., Skene A.M., Wilcox R.G., Armstrong P.W. Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction [see comments]. J Am Coll Cardiol. 27:1996;1327-1332.
176. Kennedy J.W., Martin G.V., Davis K.B., Maynard C., Stadius M., Sheehan F.H., Ritchie J.L. The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomized Trial [published erratum appears in Circulation. 1988;77:1037]. Circulation. 77:1988;345-352.
177. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet. 1:1988;545-549.
178. Timmis A.D., Griffin B., Crick J.C., Sowton E. Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: a placebo-controlled arteriographic coronary recanalization study. J Am Coll Cardiol. 10:1987;205-210.
179. Verstraete M., Bernard R., Bory M., Brower R.W., Collen D., de Bono D.P., Erbel R., Huhmann W., Lennane R.J., Lubsen J., et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet. 1:1985;842-847.
180. Wilcox R.G., von der Lippe G., Olsson C.G., Jensen G., Skene A.M., Hampton J.R. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 2:1988;525-530.
181. Bode C., Smalling R.W., Berg G., Burnett C., Lorch G., Kalbfleisch J.M., Chernoff R., Christie L.G., Feldman R.L., Seals A.A., Weaver W.D. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 94:1996;891-898.
182. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence: International Joint Efficacy Comparison of Thrombolytics [see comments] [published erratum appears in Lancet. 1995;346:980]. Lancet. 1995;346:329-336.
183. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence: International Joint Efficacy Comparison of Thrombolytics [see comments] [published erratum appears in Lancet. 1995;346:980]. Lancet. 1995;346:329-336.
184. Van de Werf F., Cannon C.P., Luyten A., Houbracken K., McCabe C.H., Berioli S., Bluhmki E., Sarelin H., Wang-Clow F., Fox N.L., Braunwald E. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. Am Heart J. 137:1999;786-791.
185. Anderson J.L., Karagounis L.A., Becker L.C., Sorensen S.G., Menlove R.L. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation. 87:1993;1829-1839.
186. Lincoff A.M., Topol E.J. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? [corrected and republished article originally printed in Circulation. 1993;87:1792-1805]. Circulation. 88:1993;1361-1374.
187. Ohman E.M., Kleiman N.S., Gacioch G., Worley S.J., Navetta F.I., Talley J.D., Anderson H.V., Ellis S.G., Cohen M.D., Spriggs D., Miller M., Kereiakes D., Yakubov S., Kitt M.M., Sigmon K.N., Califf R.M., Krucoff M.W., Topol E.J. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial [see comments]. Circulation. 95:1997;846-854.
188. Chaitman B.R., Thompson V.W., Kern M.J., Vandormael M.G., Cohen M.B., Ruocco N.A., Solomon R.E., Braunwald E. Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty: one-year TIMI phase II pilot results [published erratum appears in Am Heart J. 1990;120(6 pt 1):1486]. Am Heart J. 119:1990;213-223.
189. van den Merkhof L.F., Zijlstra F., Olsson H., Grip L., Veen G., Bar F.W., van den Brand M.J., Simoons M.L., Verheugt F.W. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty: results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol. 33:1999;1528-1532.
190. den Heijer P., Vermeer F., Ambrosioni E., Sadowski Z., Lopez-Sendon J.L., von Essen R., Beaufils P., Thadani U., Adgey J., Pierard L., Brinker J., Davies R.F., Smalling R.W., Wallentin L., Caspi A., Pangerl A., Trickett L., Hauck C., Henry D., Chew P. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation. 98:1998;2117-2125.
191. Nordt T.K., Moser M., Kohler B., Kubler W., Bode C. Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA). Thromb Haemost. 82:((suppl 1)):1999;121-123.
192. Califf R.M. Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. Am Heart J. 138:1999;S12-S15.
193. Antman E.M., Giugliano R.P., Gibson C.M., McCabe C.H., Coussement P., Kleiman N.S., Vahanian A., Adgey A.A., Menown I., Rupprecht H.J., Van der Wieken R., Ducas J., Scherer J., Anderson K., Van de Werf F., Braunwald E. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation. 99:1999;2720-2732.
194. Michels K.B., Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials [see comments]. Circulation. 91:1995;476-485.
195. Every N.R., Parsons L.S., Hlatky M., Martin J.S., Weaver W.D. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction [see comments]. N Engl J Med. 335:1996;1253-1260.
196. Cucherat M., Bonnefoy E., Tremeau G. Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction. Cochrane Database Syst Rev. 2:2000;CD001560.
197. Nunn C.M., O'Neill W.W., Rothbaum D., Stone G.W., O'Keefe J., Overlie P., Donohue B., Grines L., Browne K.F., Vlietstra R.E., Catlin T., Grines C.L. Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. J Am Coll Cardiol. 33:1999;640-646.
198. Holmes D.R. Jr, White H.D., Pieper K.S., Ellis S.G., Califf R.M., Topol E.J. Effect of age on outcome with primary angioplasty versus thrombolysis. J Am Coll Cardiol. 33:1999;412-419.
199. Stone G.W., Brodie B.R., Griffin J.J., Costantini C., Morice M.C., St Goar F.G., Overlie P.A., Popma J.J., McDonnell J., Jones D., O'Neill W.W., Grines C.L. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation. 99:1999;1548-1554.
200. Antoniucci D., Santoro G.M., Bolognese L., Valenti R., Trapani M., Fazzini P.F. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol. 31:1998;1234-1239.
201. Antoniucci D., Valenti R., Buonamici P., Santoro G.M., Leoncini M., Bolognese L., Fazzini P.F. Direct angioplasty and stenting of the infarct-related artery in acute myocardial infarction. Am J Cardiol. 78:1996;568-571.
202. Cannon A.D., Roubin G.S., Macander P.J., Agrawal S.K. Intracoronary stenting as an adjunct to angioplasty in acute myocardial infarction. J Invasive Cardiol. 3:1991;255-258.
203. Stone G.W., Brodie B.R., Griffin J.J., Morice M.C., Costantini C., St Goar F.G., Overlie P.A., Popma J.J., McDonnell J., Jones D., O'Neill W.W., Grines C.L. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. J Am Coll Cardiol. 31:1998;23-30.
204. Cannon C.P., Thompson B., McCabe C.H., Mueller H.S., Kirshenbaum J.M., Herson S., Nasmith J.B., Chaitman B.R., Braunwald E. Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III trials [see comments]. Am J Cardiol. 75:1995;977-981.
205. Boden W.E., O'Rourke R.A., Crawford M.H., Blaustein A.S., Deedwania P.C., Zoble R.G., Wexler L.F., Kleiger R.E., Pepine C.J., Ferry D.R., Chow B.K., Lavori P.W. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy [see comments]. N Engl J Med. 338:1998;1785-1792.
206. Yusuf, Flather, Pogue, Hunt, Varigos, Piegas, Avezum, Anderson, Keltai, Budaj Fox, Ceremuzynski. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation [see comments]. Lancet. 352:1998;507-514.
207. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study [see comments]. Lancet 1999;354:708-715.
208. Armstrong P.W., Fu Y., Chang W.C., Topol E.J., Granger C.B., Betriu A., Van de Werf F., Lee K.L., Califf R.M. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. Circulation. 98:1998;1860-1868.
209. Kong D.F., Califf R.M., Miller D.P., Moliterno D.J., White H.D., Harrington R.A., Tcheng J.E., Lincoff A.M., Hasselblad V., Topol E.J. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 98:1998;2829-2835.
210. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes [see comments]. N Engl J Med 1998;339:436-443.
211. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction [see comments] [published erratum appears in N Engl J Med 1998;339:415]. N Engl J Med. 1998;338:1488-1497.
212. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction [see comments] [published erratum appears in N Engl J Med 1998;339:415]. N Engl J Med. 1998;338:1488-1497.
213. Kereiakes D., Grines C., Fry E., Barr L., Matthai W., Broderick T., Lengerich R., Cohen M., Esente P. Abciximab-enoxaparin interaction during percutaneous coronary intervention: results of the NICE-1 and NICE-2 Trials. J Am Coll Cardiol. 35:2000;92A.
214. Brieger D.B., Mak K.H., Kottke-Marchant K., Topol E.J. Heparin-induced thrombocytopenia. J Am Coll Cardiol. 31:1998;1449-1459.
215. Cohen M., Demers C., Gurfinkel E.P., Turpie A.G., Fromell G.J., Goodman S., Langer A., Califf R.M., Fox K.A., Premmereur J., Bigonzi G.J. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease [see comments]. N Engl J Med. 337:1997;447-452.
216. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593-1601. [210a] Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study. Circulation. 1997;96:61-68. [210b] Fraxis Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. Eur Heart J. 1999;20:1553-1562.
217. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593-1601. [210a] Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study. Circulation. 1997;96:61-68. [210b] Fraxis Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. Eur Heart J. 1999;20:1553-1562.
218. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593-1601. [210a] Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study. Circulation. 1997;96:61-68. [210b] Fraxis Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. Eur Heart J. 1999;20:1553-1562.
219. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study [see comments] [published erratum appears in Lancet. 1999;354:1478]. Lancet. 354:1999;701-707.
220. Hochman J.S., Sleeper L.A., Webb J.G., Sanborn T.A., White H.D., Talley J.D., Buller C.E., Jacobs A.K., Slater J.N., Col J., McKinlay S.M., LeJemtel T.H. Early revascularization in acute myocardial infarction complicated by cardiogenic shock [see comments]. N Engl J Med. 341:1999;625-634.
221. Holmes D.R. Jr, Bates E.R., Kleiman N.S., Sadowski Z., Horgan J.H., Morris D.C., Califf R.M., Berger P.B., Topol E.J. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. J Am Coll Cardiol. 26:1995;668-674.
222. Bates E.R., Topol E.J. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol. 18:1991;1077-1084.
223. Ellis S.G., O'Neill W.W., Bates E.R., Walton J.A. Jr, Nabel E.G., Werns S.W., Topol E.J. Implications for patient triage from survival and left ventricular functional recovery analyses in 500 patients treated with coronary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 13:1989;1251-1259.
224. Moosvi A.R., Khaja F., Villanueva L., Gheorghiade M., Douthat L., Goldstein S. Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction [see comments]. J Am Coll Cardiol. 19:1992;907-914.
225. Lee L., Bates E.R., Pitt B., Walton J.A., Laufer N., O'Neill W.W. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation. 78:1988;1345-1351.
226. Verna E., Repetto S., Boscarini M., Ghezzi I., Binaghi G. Emergency coronary angioplasty in patients with severe left ventricular dysfunction or cardiogenic shock after acute myocardial infarction. Eur Heart J. 10:1989;958-966.
227. Califf R.M., Bengtson J.R. Cardiogenic shock. N Engl J Med. 330:1994;1724-1730.
228. Berger P.B., Ryan T.J. Inferior myocardial infarction: high-risk subgroups. Circulation. 81:1990;401-411.
229. Kinch J.W., Ryan T.J. Right ventricular infarction [see comments]. N Engl J Med. 330:1994;1211-1217.
230. Zehender M., Kasper W., Kauder E., Schonthaler M., Geibel A., Olschewski M., Just H. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction [see comments]. N Engl J Med. 328:1993;981-988.
231. Berger P.B., Ruocco N.A. Jr, Ryan T.J., Jacobs A.K., Zaret B.L., Wackers F.J., Frederick M.M., Faxon D.P. Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the Thrombolysis In Myocardial Infarction [TIMI] II trial). Am J Cardiol. 71:1993;1148-1152.
232. Goldstein J.A., Barzilai B., Rosamond T.L., Eisenberg P.R., Jaffe A.S. Determinants of hemodynamic compromise with severe right ventricular infarction. Circulation. 82:1990;359-368.
233. Dalen J., Hirsch J. ACCP Consensus Conference on Antithrombotic Therapy. Chest. 114:((5 suppl)):1998;439S-769S.
234. Collins R., MacMahon S., Flather M., Baigent C., Remvig L., Mortensen S., Appleby P., Godwin J., Yusuf S., Peto R. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ. 313:1996;652-659.
235. Hsia J., Hamilton W.P., Kleiman N., Roberts R., Chaitman B.R., Ross A.M. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction [see comments]. N Engl J Med. 323:1990;1433-1437.
236. Tanne D., Reicher-Reiss H., Boyko V., Behar S. Stroke risk after anterior wall acute myocardial infarction. Am J Cardiol. 76:1995;825-826.
237. Loh E., Sutton M.S., Wun C.C., Rouleau J.L., Flaker G.C., Gottlieb S.S., Lamas G.A., Moye L.A., Goldhaber S.Z., Pfeffer M.A. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 336:1997;251-257.
238. Metoprolol in acute myocardial infarction (MIAMI): a randomised placebo-controlled international trial. Eur Heart J. 6:1985;199-226.
239. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 2:1986;57-66.
240. Rehnqvist N., Olsson G., Erhardt L., Ekman A.M. Metoprolol in acute myocardial infarction reduces ventricular arrhythmias both in the early stage and after the acute event. Int J Cardiol. 15:1987;301-308.
241. Herlitz J., Edvardsson N., Holmberg S., Ryden L., Waagstein F., Waldenstrom A., Swedberg K., Hjalmarson A. Goteborg Metoprolol Trial: effects on arrhythmias. Am J Cardiol. 53:1984;27D-31D.
242. Roberts R., Rogers W.J., Mueller H.S., Lambrew C.T., Diver D.J., Smith H.C., Willerson J.T., Knatterud G.L., Forman S., Passamani E., et al. Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study [see comments]. Circulation. 83:1991;422-437.
243. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial [see comments]. J Am Coll Cardiol. 27:1996;337-344.
244. Ferguson J.J., Diver D.J., Boldt M., Pasternak R.C. Significance of nitroglycerin-induced hypotension with inferior wall acute myocardial infarction. Am J Cardiol. 64:1989;311-314.
245. Muller J.E., Morrison J., Stone P.H., Rude R.E., Rosner B., Roberts R., Pearle D.L., Turi Z.G., Schneider J.F., Serfas D.H., et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation. 69:1984;740-747.
246. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II) [see comments]. Am J Cardiol. 1990;66:779-785.
247. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 319:1988;385-392.
248. Boden W.E., van Gilst W.H., Scheldewaert R.G., Starkey I.R., Carlier M.F., Julian D.G., Whitehead A., Bertrand M.E., Col J.J., Pedersen O.L., Lie K.I., Santoni J.P., Fox K.M. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial: Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT). Lancet. 355:2000;1751-1756.
249. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction [see comments]. Lancet. 343:1994;1115-1122.
250. Oral captopril versus placebo among 14,962 patients with suspected acute myocardial infarction: a multicenter, randomized, double-blind, placebo controlled clinical trial. Chin Med J. 110:1997;834-838.
251. Ambrosioni E., Borghi C., Magnani B. Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction [see comments]. N Engl J Med. 332:1995;80-85.
252. Borghi C., Marino P., Zardini P., Magnani B., Collatina S., Ambrosioni E. Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. Am Heart J. 136:1998;213-225.
253. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials [see comments]. Circulation. 97:1998;2202-2212.
254. Swedberg K., Held P., Kjekshus J., Rasmussen K., Ryden L., Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) [see comments]. N Engl J Med. 327:1992;678-684.
255. Teo K.K., Yusuf S., Collins R., Held P.H., Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials [see comments]. BMJ. 303:1991;1499-1503.
256. Woods K.L., Fletcher S., Roffe C., Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) [see comments]. Lancet. 339:1992;1553-1558.
257. Antman E.M. Magnesium in acute myocardial infarction: overview of available evidence. Am Heart J. 132:(487-495):1996;496-502.
258. Rationale and design of the Magnesium in Coronaries (MAGIC) study: a clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarction. Am Heart J. 139:2000;10-14.
259. Sodi-Pallares D., Ponce de Leon J., Bisteni A., Medrano G.A. Potassium, glucose, and insulin in myocardial infarction. Lancet. 1:1969;1315-1316.
260. Maroko P.R., Libby P., Sobel B.E., Bloor C.M., Sybers H.D., Shell W.E., Covell J.W., Braunwald E. Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation. 45:1972;1160-1175.
261. Opie L.H. Myocardial infarct size, II: comparison of anti-infarct effects of beta-blockade, glucose-insulin-potassium, nitrates, and hyaluronidase. Am Heart J. 100:1980;531-552.
262. Rackley C.E., Russell R.O. Jr, Rogers W.J., Mantle J.A., McDaniel H.G., Papapietro S.E. Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction. Am Heart J. 102:1981;1038-1049.
263. Rogers W.J., Stanley A.W. Jr, Breinig J.B., Prather J.W., McDaniel H.G., Moraski R.E., Mantle J.A., Russell R.O. Jr, Rackley C.E. Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulin-potassium infusion. Am Heart J. 92:1976;441-454.
264. Fath-Ordoubadi F., Beatt K.J. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials [see comments]. Circulation. 96:1997;1152-1156.
265. Malmberg K., Ryden L., Hamsten A., Herlitz J., Waldenstrom A., Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction [see comments]. Eur Heart J. 17:1996;1337-1344.
266. Apstein C.S., Taegtmeyer H. Glucose-insulin-potassium in acute myocardial infarction: the time has come for a large, prospective trial [editorial; comment]. Circulation. 96:1997;1074-1077.
267. Diaz R., Paolasso E.A., Piegas L.S., Tajer C.D., Moreno M.G., Corvalan R., Isea J.E., Romero G. Metabolic modulation of acute myocardial infarction. Circulation. 98:1998;2227-2234.
268. Ceremuzynski L., Budaj A., Czepiel A., Burzykowski T., Achremczyk P., Smielak-Korombel W., Maciejewicz J., Dziubinska J., Nartowicz E., Kawka-Urbanek T., Piotrowski W., Hanzlik J., Cieslinski A., Kawecka-Jaszcz K., Gessek J., Wrabec K. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther. 13:1999;191-200.
269. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus [see comments]. BMJ. 314:1997;1512-1515.
270. MacMahon S., Collins R., Peto R., Koster R.W., Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized, controlled trials. JAMA. 260:1988;1910-1916.
271. Belardinelli L., Shryock J., West G.A., Clemo H.F., DiMarco J.P., Berne R.M. Effects of adenosine and adenine nucleotides on the atrioventricular node of isolated guinea pig hearts. Circulation. 70:1984;1083-1091.
272. Feigl D., Ashkenazy J., Kishon Y. Early and late atrioventricular block in acute inferior myocardial infarction. J Am Coll Cardiol. 4:1984;35-38.
273. Shah P.K., Nalos P., Peter T. Atropine resistant post infarction complete AV block: possible role of adenosine and improvement with aminophylline. Am Heart J. 113:1987;194-195.
274. Goldberg R.J., Seeley D., Becker R.C., Brady P., Chen Z.Y., Osganian V., Gore J.M., Alpert J.S., Dalen J.E. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J. 119:1990;996-1001.
275. Behar S., Reicher-Reiss H., Abinader E., Agmon J., Barzilai J., Friedman Y., Kaplinsky E., Kauli N., Kishon Y., Palant A., et al. Long-term prognosis after acute myocardial infarction in patients with left ventricular hypertrophy on the electrocardiogram. Am J Cardiol. 69:1992;985-990.
276. Eldar M., Canetti M., Rotstein Z., Boyko V., Gottlieb S., Kaplinsky E., Behar S. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. Circulation. 97:1998;965-970.
277. Madias J.E., Patel D.C., Singh D. Atrial fibrillation in acute myocardial infarction: a prospective study based on data from a consecutive series of patients admitted to the coronary care unit. Clin Cardiol. 19:1996;180-186.
278. Nielsen F.E., Andersen H.H., Gram-Hansen P., Sorensen H.T., Klausen I.C. The relationship between ECG signs of atrial infarction and the development of supraventricular arrhythmias in patients with acute myocardial infarction. Am Heart J. 123:1992;69-72.
279. Hod H., Lew A.S., Keltai M., Cercek B., Geft I.L., Shah P.K., Ganz W. Early atrial fibrillation during evolving myocardial infarction: a consequence of impaired left atrial perfusion. Circulation. 75:1987;146-150.
280. Widimsky P., Gregor P. Recent atrial fibrillation in acute myocardial infarction: a sign of pericarditis. Cor Vasa. 35:1993;230-232.
281. Nielsen F.E., Sorensen H.T., Christensen J.H., Ravn L., Rasmussen S.E. Reduced occurrence of atrial fibrillation in acute myocardial infarction treated with streptokinase. Eur Heart J. 12:1991;1081-1083.
282. Behar S., Zahavi Z., Goldbourt U., Reicher-Reiss H. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. Eur Heart J. 13:1992;45-50.